https://www.selleckchem.com/products/th-257.html
To evaluate the effect of perioperative meloxicam IV 30 mg on opioid consumption in primary total knee arthroplasty (TKA). Multicenter, randomized, double-blind, placebo-controlled trial. 181 adults undergoing elective primary TKA. Subjects received meloxicam 30 mg or placebo via an IV bolus every 24 hours, the first dose administered prior to surgery as part of a multimodal pain management protocol. The primary efficacy parameter was total opioid use from end of surgery through 24 hours. Meloxicam IV was associated with less opioid use
Like
Comment
Share
